White paper

The Adesis Catalog of Advanced Heterocycles initiative began in 2003 to support medicinal and combinatorial chemistry efforts in the drug industry. The mission is to provide new building blocks and intermediates, including those known in the literature but not readily available, to help solve some of the problems incurred during drug discovery. Such problems include protein-binding, enhance solubility in physiological media, and/or modified P450 metabolic processes. Adesis hopes to fill this niche using a concise progression of core structures, containing minimally two functional groups for orthogonal elaboration, which will be synthetic linchpins for new bioactive compounds. These functionalized azoles (azaindoles, naphthyridines, pyridines, pyrrolidines, imidazo-pyridines, furopyridines, pyrido-pyrazine, pyrido-oxazines, dihydro-pyranopyridines, and pyrido-oxazinones), based upon Adesis' extensive proprietary synthetic expertise, are provided at lower cost vs. custom synthesis. The design of the catalog compounds is governed largely by scientific (pharmaceutical and chemistry) and business considerations, that leverage Adesis synthesis technologies, many of which have been developed by Adesis. In order to provide a broad range of intermediates, Adesis also offers literature compounds that are thematically relevant to the Advanced Intermediates initiative.